{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:17:38Z","timestamp":1786457858292,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,9,25]],"date-time":"2008-09-25T00:00:00Z","timestamp":1222300800000},"content-version":"am","delay-in-days":268,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.biopsych.2007.04.034","type":"journal-article","created":{"date-parts":[[2007,6,29]],"date-time":"2007-06-29T13:56:33Z","timestamp":1183125393000},"page":"92-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Phencyclidine-Induced Cognitive Deficits in Mice Are Improved by Subsequent Subchronic Administration of the Novel Selective \u03b17 Nicotinic Receptor Agonist SSR180711"],"prefix":"10.1016","volume":"63","author":[{"given":"Kenji","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Ishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Kobashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Takahagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Iyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2007.04.034_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib2","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMra035458","article-title":"Schizophrenia","volume":"349","author":"Freedman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2007.04.034_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00213-003-1709-2","article-title":"The NMDA receptor glycine modulatory site: A therapeutic target for improving cognition and reducing negative symptoms in schizophrenia","volume":"174","author":"Coyle","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2007.04.034_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.schres.2004.07.005","article-title":"Neurocognitive impairment across the lifespan in schizophrenia: An update","volume":"74","author":"Kurtz","year":"2005","journal-title":"Schizophrenia Res"},{"key":"10.1016\/j.biopsych.2007.04.034_bib6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib7","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","article-title":"Glutamate receptor dysfunction and schizophrenia","volume":"52","author":"Olney","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/hrp\/7.3.125","article-title":"NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders","volume":"7","author":"Krystal","year":"1999","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archpsyc.60.6.572","article-title":"Decreased serum levels of D-serine in patients with schizophrenia: Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia","volume":"60","author":"Hashimoto","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib10","first-page":"147","article-title":"Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs","volume":"4","author":"Hashimoto","year":"2004","journal-title":"Curr Med Chem - CNS Agents"},{"key":"10.1016\/j.biopsych.2007.04.034_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/1573400054065569","article-title":"Dysfunction of glia-neuron communication in pathophysiology of schizophrenia","volume":"1","author":"Hashimoto","year":"2005","journal-title":"Curr Psychiatry Rev"},{"key":"10.1016\/j.biopsych.2007.04.034_bib12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archpsyc.62.9.985","article-title":"Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: Implications for glutamatergic and dopaminergic model psychoses and cognitive function","volume":"62","author":"Krystal","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2007.04.034_bib14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol","volume":"519","author":"Hashimoto","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2007.04.034_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2006.09.055","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: Role of \u03b17 nicotinic receptors","volume":"553","author":"Hashimoto","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2007.04.034_bib16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.npp.1301047","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors","volume":"32","author":"Hashimoto","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2007.04.034_bib17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1073\/pnas.94.2.587","article-title":"Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus","volume":"94","author":"Freedman","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2007.04.034_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0891-0618(00)00109-5","article-title":"The \u03b17-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia","volume":"20","author":"Freedman","year":"2000","journal-title":"J Chem Neuroanat"},{"key":"10.1016\/j.biopsych.2007.04.034_bib19","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archpsyc.59.12.1085","article-title":"Association of promoter variants in the \u03b17 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia","volume":"59","author":"Leonard","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0163-7258(01)00161-9","article-title":"Neuronal nicotinic acetylcholine receptor subunit knockout mice: Physiological and behavioral phenotypes and possible clinical implications","volume":"92","author":"Picciotto","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2007.04.034_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/1568007024606168","article-title":"Nicotinic agonists and psychosis","volume":"1","author":"Simosky","year":"2002","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.biopsych.2007.04.034_bib22","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/sj.npp.1300466","article-title":"Evidence of association between smoking and \u03b17 nicotinic receptor subunit gene in schizophrenia patients","volume":"29","author":"De Luca","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2007.04.034_bib23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.npp.1300393","article-title":"Nicotine improves sustained attention in mice: Evidence for involvement of the \u03b17 nicotinic acetylcholine receptor","volume":"29","author":"Young","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2007.04.034_bib24","first-page":"54","article-title":"\u03b17 nicotinic receptor agonists: Potential new candidates for the treatment of schizophrenia","volume":"74","author":"Martin","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2007.04.034_bib25","first-page":"171","article-title":"\u03b17 Nicotinic receptor agonists as potential therapeutic drugs for schizophrenia","volume":"5","author":"Hashimoto","year":"2005","journal-title":"Curr Med Chem - CNS Agents"},{"key":"10.1016\/j.biopsych.2007.04.034_bib26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00213-005-0164-7","article-title":"Nicotinic effects on cognitive function: Behavioral characterization, pharmacological specification, and anatomic localization","volume":"184","author":"Levin","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2007.04.034_bib27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00008877-199911000-00014","article-title":"AR-R17779, and \u03b17 nicotinic agonist, improves learning and memory in rats","volume":"10","author":"Levin","year":"1999","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2007.04.034_bib28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-003-1668-7","article-title":"AR-R 17779 improves social recognition in rats by activation of nicotinic \u03b17 receptors","volume":"172","author":"Van Kampen","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2007.04.034_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0166-4328(00)00305-3","article-title":"Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task","volume":"117","author":"Grottick","year":"2000","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2007.04.034_bib30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0006-3223(01)01093-9","article-title":"Intragastric DMXB-A, an \u03b17 nicotinic agonist, improves deficient sensory inhibition in DBA\/2 mice","volume":"50","author":"Simosky","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-005-0142-0","article-title":"Tropisetron improves deficient inhibitory auditory processing in DBA\/2 mice: role of \u03b17 nicotinic acetylcholine receptors","volume":"183","author":"Hashimoto","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2007.04.034_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.schres.2004.12.016","article-title":"Tropisetron improves deficits in auditory P50 suppression in schizophrenia","volume":"76","author":"Koike","year":"2005","journal-title":"Schizophrenia Res"},{"key":"10.1016\/j.biopsych.2007.04.034_bib33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/archpsyc.63.6.630","article-title":"Proof-of-concept trial of an \u03b17 nicotinic agonist in schizophrenia","volume":"63","author":"Olincy","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.npp.1301189","article-title":"SSR180711, a novel selective \u03b17 nicotinic receptor partial agonist: (1) binding and functional profile","volume":"32","author":"Bilton","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2007.04.034_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.npp.1301188","article-title":"SSR180711, a novel selective \u03b17 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia","volume":"32","author":"Pichat","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2007.04.034_bib36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.biopsych.2005.07.031","article-title":"Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: A neurodevelopmental animal model of schizophrenia","volume":"59","author":"Ozawa","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0006-3223(94)00252-X","article-title":"Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia","volume":"38","author":"Freedman","year":"1995","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib38","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0006-3223(03)00348-2","article-title":"Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia","volume":"54","author":"Martin-Ruiz","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib39","series-title":"Neurogenetics of Psychiatric Disorders","first-page":"81","article-title":"Candidate genes and models: Chapter 6. Neurotransmission","author":"Hashimoto","year":"2007"},{"key":"10.1016\/j.biopsych.2007.04.034_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archpsyc.1990.01810140081011","article-title":"Sensorimotor gating and schizophrenia","volume":"47","author":"Braff","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2007.04.034_bib41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0893-133X(95)00178-G","article-title":"Genetic correlation of inhibitory gating of hippocampal auditory evoked response and \u03b1-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains","volume":"15","author":"Stevens","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2007.04.034_bib42","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1124\/jpet.104.076968","article-title":"The selective \u03b17 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats","volume":"312","author":"Hajos","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2007.04.034_bib43","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1021\/jm049188d","article-title":"Discovery of the \u03b17 nicotinic acetylcholine receptor agonists","volume":"48","author":"Tatsumi","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopsych.2007.04.034_bib44","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1021\/jm060249c","article-title":"(R)-3\u2019-(3-Methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5\u2019-oxazolidin]-2\u2019-one, a novel and potent \u03b17 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties","volume":"49","author":"Tatsumi","year":"2006","journal-title":"J Med Chem"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322307004246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322307004246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T14:52:11Z","timestamp":1757775131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322307004246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0006322307004246"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2007.04.034","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phencyclidine-Induced Cognitive Deficits in Mice Are Improved by Subsequent Subchronic Administration of the Novel Selective \u03b17 Nicotinic Receptor Agonist SSR180711","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2007.04.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}